Tryptophan

Tryptophan

SCHEMBL3497630

CC(C)[C@H](N)C(=O)O.C[C@H](N)C(=O)O.N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.78
MAPT P10636 3/20 0.78
KMT2A Q03164 3/20 0.78
LMNA P02545 2/20 0.78
TSHR P16473 2/20 0.78
BLM P54132 2/20 0.78
PMP22 Q01453 2/20 0.78
MEN1 O00255 2/20 0.78
MPO P05164 1/20 0.78
HIF1A Q16665 1/20 0.78
APAF1 O14727 1/20 0.62
POLB P06746 1/20 0.62
RECQL P46063 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
CTSC P53634 1/20 0.57
HTR2A P28223 3/20 0.57
HTR1A P08908 2/20 0.57
HTR2C P28335 2/20 0.57
SLC6A4 P31645 2/20 0.57
HTR7 P34969 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Tryptophan SCHEMBL8814131 0.97 KDM4E (0.82) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL4852913 0.97 KDM4E (0.82) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL10527499 0.97 KDM4E (0.82) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL11880165 0.97 KDM4E (0.82) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL4852909 0.97 KDM4E (0.82) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL10527472 0.96 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL5065251 0.94 KDM4E (0.89) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL5065247 0.94 KDM4E (0.89) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL7154073 0.93 KDM4E (0.74) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL22091568 0.93 KDM4E (0.74) KDM4EMAPTKMT2ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143364-A1 Chimeric Antibodies, Compositions and Methods for Treating Cocaine-Related Disorders VYBION, INC. (US) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143364-A1 Chimeric Antibodies, Compositions and Methods for Treating Cocaine-Related Disorders CES2, CHRNA5, CHRNA3 KDM4E 1096/4885MAPT 61/4885KMT2A 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.